ATAI Life Sciences N.V.

ATAI | $1.875 -4.82% -5.07% 830K

(0.0% 1d) (8.1% 1m) (0.0% 1y) (0.0% 2d) (-5.6% 3d) (1.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 313,898,732
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | $1.33 0.0% 110K

Manufacturing

(0.0% 1d) (-11.3% 1m) (59.9% 1y) (0.0% 2d) (0.0% 3d) (0.8% 7d) (-59.59% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 29,392,132

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception food

add to watch list Paper trade email alert is off

ReShape Lifesciences Inc.

RSLS | $0.1705 3.93% 120K

Manufacturing

(0.0% 1d) (-6.6% 1m) (-92.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-34.99% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 3,999,434
https://www.obalon.com
Sec Filling | Patents | 2 employees

(United States) Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.

add to watch list Paper trade email alert is off